A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) (NCT07589595)
A Phase 2 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Donanemab in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.
Who can join: Review the eligibility criteria below.
Location: TrialSphere Corp — Chandler, Arizona
Age range: 55 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (72 Sites)
Showing the first 25 of 72 sites.
- TrialSphere Corp — Chandler, Arizona
- HonorHealth Research Institute — Scottsdale, Arizona
- Profound Research LLC — Carlsbad, California
- Irvine Clinical Research — Irvine, California
- UCSD - Altman Clinical and Translational Research Institute (ACTRI) — La Jolla, California
- Stanford Neuroscience Health Center — Palo Alto, California
- CenExel Rocky Mountain Clinical Research — Englewood, Colorado
- Ki Health Partners, LLc, dba New England Institute for Clinical Research — Stamford, Connecticut
- JEM Research Institute — Atlantis, Florida
- VIN - Aventura — Aventura, Florida
- Brain Matters Research — Delray Beach, Florida
- Neuropsychiatric Research Center of Southwest Florida — Fort Myers, Florida
- Norman Fixel Institute for Neurological Diseases (FIND) — Gainesville, Florida
- Mayo Clinic in Florida — Jacksonville, Florida
- K2 Medical Research ORLANDO — Maitland, Florida
- BRP-Kendal Lakes — Miami, Florida
- Renstar Medical Research — Ocala, Florida
- Charter Research - Orlando — Orlando, Florida
- Axiom Brain Health LLC — Tampa, Florida
- Palm Beach Neurology — West Palm Beach, Florida
- Conquest Research — Winter Park, Florida
- Indiana University Health Neuroscience Center — Indianapolis, Indiana
- The University of Kansas - Clinical Research Center — Fairway, Kansas
- Massachusetts General Hospital - Charlestown — Charlestown, Massachusetts
- K2 Medical Research - Foxborough — Foxborough, Massachusetts
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cognitive Dysfunction
- PREsurgical Cognitive Evaluation Via Digital clockfacEdrawing — Gainesville, Florida
- Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment — Los Angeles, California
- Fareon Open Label Device Clinical Trial — New York, New York
- Stem Cell Therapy for Early Alzheimer's Disease — Houston, Texas
- ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults — New Brunswick, New Jersey
Explore by condition: All Cognitive Dysfunction clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.